169 related articles for article (PubMed ID: 38662207)
1. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Tazoe K; Harada N; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Hirose A; Nakamae M; Nishimoto M; Nakashima Y; Koh H; Hino M; Nakamae H
Ann Hematol; 2024 Jun; 103(6):2059-2072. PubMed ID: 38662207
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
4. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
Mekinian A; Grignano E; Braun T; Decaux O; Liozon E; Costedoat-Chalumeau N; Kahn JE; Hamidou M; Park S; Puéchal X; Toussirot E; Falgarone G; Launay D; Morel N; Trouiller S; Mathian A; Gombert B; Schoindre Y; Lioger B; De Wazieres B; Amoura Z; Buchdaul AL; Georgin-Lavialle S; Dion J; Madaule S; Raffray L; Cathebras P; Piette JC; Rose C; Ziza JM; Lortholary O; Montestruc F; Omouri M; Denis G; Rossignol J; Nimubona S; Adès L; Gardin C; Fenaux P; Fain O
Rheumatology (Oxford); 2016 Feb; 55(2):291-300. PubMed ID: 26350487
[TBL] [Abstract][Full Text] [Related]
5. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
7. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Bell JA; Galaznik A; Huelin R; Stokes M; Guo Y; Fram RJ; Faller DV
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):e157-e166. PubMed ID: 29475821
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
9. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation.
Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Lin JS; Chiou TJ; Liu CY; Gau JP
J Chin Med Assoc; 2020 Mar; 83(3):238-244. PubMed ID: 31904659
[TBL] [Abstract][Full Text] [Related]
10. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.
Itonaga H; Kida M; Hamamura A; Uchida N; Ozawa Y; Fukuda T; Ueda Y; Kataoka K; Katayama Y; Ota S; Matsuoka KI; Kondo T; Eto T; Kanda J; Ichinohe T; Atsuta Y; Miyazaki Y; Ishiyama K
Hematol Oncol; 2022 Oct; 40(4):752-762. PubMed ID: 35299289
[TBL] [Abstract][Full Text] [Related]
11. [Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes].
Gournay V; Robin M
Bull Cancer; 2023 Nov; 110(11):1168-1175. PubMed ID: 37516649
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
14. Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation.
Zhu P; Lai X; Liu L; Shi J; Yu J; Zhao Y; Yang L; Yang T; Zheng W; Sun J; Wu W; Zhao Y; Cai Z; Huang H; Luo Y
J Transl Med; 2024 Mar; 22(1):275. PubMed ID: 38481248
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes and prognostic factors of myelodysplastic syndrome patients with allogeneic hematopoietic stem cell transplantation].
Liu ZX; Lyu MN; Wang QQ; Zhai WH; Pang AM; Ma QL; Yang DL; He Y; Zhang RL; Huang Y; Wei JL; Feng SZ; Jiang EL; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):484-489. PubMed ID: 31340621
[No Abstract] [Full Text] [Related]
16. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
[No Abstract] [Full Text] [Related]
17. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Yu ZP; Ding JH; Sun AN; Ge Z; Chen BA; Wu DP
Stem Cells Dev; 2017 Aug; 26(15):1132-1139. PubMed ID: 28494646
[TBL] [Abstract][Full Text] [Related]
19. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.
Chien SH; Yao M; Li CC; Chang PY; Yu MS; Huang CE; Tan TD; Lin CH; Yeh SP; Li SS; Wang PN; Liu YC; Gau JP
J Formos Med Assoc; 2021 Dec; 120(12):2144-2152. PubMed ID: 33423899
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
Front Med; 2019 Jun; 13(3):354-364. PubMed ID: 30680605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]